ACA
SRNE

Avoro Capital Advisors’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Avoro Capital Advisors’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-416,230
Closed -$832K – 51
2017
Q2 		$832K Sell
416,230
-775,900
-65% -$1.51M 0.11% 39
2017
Q1 		$4.71M Sell
1,192,130
-263,926
-18% -$1.32M 0.6% 31
2016
Q4 		$7.13M Sell
1,456,056
-75,217
-5% -$452K 1.44% 22
2016
Q3 		$11.9M Sell
1,531,273
-124,001
-7% -$835K 2.08% 18
2016
Q2 		$9.27M Buy
1,655,274
+509,495
+44% +$3.26M 2.06% 16
2016
Q1 		$6.16M Sell
1,145,779
-800
-0.1% -$4.65K 2.15% 16
2015
Q4 		$9.99M Sell
1,146,579
-1,004,858
-47% -$8.48M 3.44% 10
2015
Q3 		$18.1M Sell
2,151,437
-35,083
-2% -$559K 4.69% 9
2015
Q2 		$38.5M Sell
2,186,520
-27,523
-1% -$354K 10.61% 2
2015
Q1 		$25.6M Buy
2,214,043
+1,303,943
+143% +$15.1M 9.82% 3
2014
Q4 		$9.16M Buy
+910,100
New +$4.61M 6.21% 6

Other funds holding SRNE

WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IP
Intellectus Partners San Francisco, California $578M AUM 49.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Avoro Capital Advisors's SRNE Position: Q3 2017 in Review

Avoro Capital Advisors sold out of Sorrento Therapeutics, Inc. (SRNE) in Q3 2017, closing a stake of 416,230 shares — an estimated $832K sold.

Avoro Capital Advisors first reported a position in SRNE in Q4 2014 and held it in 11 quarters. The position peaked at $38.5M in Q2 2015. 37 funds tracked by Wall St. Rank hold SRNE as of Q3 2017.

  • Avoro Capital Advisors reported no remaining Sorrento Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • Avoro Capital Advisors sold 416,230 Sorrento Therapeutics, Inc. shares in Q3 2017, an estimated $832K.
  • Avoro Capital Advisors first reported a position in Sorrento Therapeutics, Inc. in Q4 2014 and held it in 11 quarters.
  • Avoro Capital Advisors's Sorrento Therapeutics, Inc. position peaked at $38.5M in Q2 2015.
  • 37 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q3 2017.

Based on Avoro Capital Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.